EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Combined BRAF, MEK, and heat‐shock protein 90 inhibition in advanced BRAF V600 ‐mutant melanoma

Zeynep Eroglu iD, Y Ann Chen, Inna Smalley, Jiannong Li, Joseph K Markowitz, Andrew S Brohl, Leticia Tetteh, Hayley Taylor, Vernon K Sondak iD, Nikhil I Khushalani, Keiran S M Smalley iD

Cancer · 2024-01 · 130 (2) · 232-243

DOI: 10.1002/cncr.35029 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer, online erschienen am 30.09.2023. Verfasst von Zeynep Eroglu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cutaneous Oncology, The Moffitt Cancer Center & Research Institute, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Melanoma, Exanthema, Skin Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Resistance to BRAF and MEK inhibitors in BRAF V600 ‐mutant melanoma is common. Multiple resistance mechanisms involve heat‐shock protein 90 (HSP90) clients, and a phase 1 study of vemurafenib with the HSP90 inhibitor XL888 in patients with advanced melanoma showed activity equivalent to that of BRAF and MEK inhibitors.

Methods

Vemurafenib (960 mg orally twice daily) and cobimetinib (60 mg orally once daily for 21 of 28 days) with escalating dose cohorts of XL888 (30, 45, 60, or 90 mg orally twice weekly) was investigated in a phase 1 trial of advanced melanoma, with a modified Ji dose‐escalation design.

Results

Twenty‐five patients were enrolled. After two dose‐limiting toxicities (DLTs) (rash and acute kidney injury) in the first cohort, lower doses of vemurafenib (720 mg) and cobimetinib (40 mg) were investigated with the same XL888 doses. Three DLTs (rash) were observed in 12 patients in the XL888 60‐mg cohort, and this was determined as the maximum tolerated dose. Objective responses were observed in 19 patients (76%), and the median progression‐free survival was 7.6 months, with a 5‐year progression‐free survival rate of 20%. The median overall survival was 41.7 months, with a 5‐year overall survival rate of 37%. Single‐cell RNA sequencing was performed on baseline and on‐treatment biopsies; treatment was associated with increased immune cell influx (CD4‐positive and CD8‐positive T cells) and decreased melanoma cells.

Conclusions

Combined vemurafenib and cobimetinib plus XL888 had significant toxicity, requiring frequent dose reductions, which may have contributed to the relatively low progression‐free survival despite a high tumor response rate. Given overlapping toxicities, caution must be used when combining HSP90 inhibitors with BRAF and MEK inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaExanthemaSkin NeoplasmsHumansVemurafenibProto-Oncogene Proteins B-rafAntineoplastic Combined Chemotherapy ProtocolsProtein Kinase InhibitorsHeat-Shock ProteinsMitogen-Activated Protein Kinase KinasesMutation

Stichwörter der Autor:innen

BRAFMEKheat-shock protein 90 (HSP90)melanomasingle cell

Substanzen

VemurafenibProto-Oncogene Proteins B-rafProtein Kinase InhibitorsHeat-Shock ProteinsMitogen-Activated Protein Kinase KinasesBRAF protein, human

Autor:innen und Institutionen

  • Department of Cutaneous Oncology, The Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
  • Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.
  • Department of Biostatistics and Bioinformatics, The Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
  • Department of Cancer Physiology, The Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
  • Department of Tumor Biology, The Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.

ORCID-Profile: Zeynep Eroglu, Vernon K Sondak, Keiran S M Smalley

Förderung

  • NCI NIH HHS

Zitieren

APA

Eroglu, Z., Chen, Y. A., Smalley, I., Li, J., Markowitz, J. K., Brohl, A. S., Tetteh, L., Taylor, H., Sondak, V. K., Khushalani, N. I., & Smalley, K. S. M. (2024). Combined BRAF, MEK, and heat‐shock protein 90 inhibition in advanced BRAF V600 ‐mutant melanoma. Cancer, 130(2), 232-243. https://doi.org/10.1002/cncr.35029

Vancouver

Eroglu Z, Chen YA, Smalley I, Li J, Markowitz JK, Brohl AS, et al. Combined BRAF, MEK, and heat‐shock protein 90 inhibition in advanced BRAF V600 ‐mutant melanoma. Cancer. 2024;130(2):232-243. doi:10.1002/cncr.35029

BibTeX
@article{Eroglu2024,
  author = {Eroglu, Zeynep and Chen, Y Ann and Smalley, Inna and Li, Jiannong and Markowitz, Joseph K and Brohl, Andrew S and Tetteh, Leticia and Taylor, Hayley and Sondak, Vernon K and Khushalani, Nikhil I and Smalley, Keiran S M},
  title = {Combined BRAF, MEK, and heat‐shock protein 90 inhibition in advanced BRAF V600 ‐mutant melanoma},
  journal = {Cancer},
  year = {2024},
  volume = {130},
  number = {2},
  pages = {232--243},
  doi = {10.1002/cncr.35029}
}
Kostenlos starten →